News & Publications

WilmerHale Reps Editas Medicine in $94.4 Million IPO

  • 2.3.2016

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016. The IPO was the first in the US in 2016.

The WilmerHale team on the transaction was led by Partners Steven D. Singer and Rosemary G. Reilly and included Counsel Jeffries Oliver-Li, and Associates Britt Eichner and Brett Bromann (corporate); as well as Partner Kim Wethly and Counsel Ciara Baker (tax). 

See other News & Publications related to:

See related industries:

Life Sciences